GleamWall
中文EN

PTHS Pelthos Therapeutics Inc.

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1919246 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-231.0%
TTM EPS YoY-32.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin83.2%
Operating margin-101.6%
Net margin-152.2%
FCF margin-63.5%
EBITDA margin-98.9%

Returns

ROE-299.8%
ROA-61.2%
ROIC (approx.)-408.1%
Asset turnover0.40x

Leverage & solvency

Liabilities / assets104.8%
Debt / equity—
Current ratio1.78x
Interest coverage-6.26x

Cash quality & payout

Operating cash flow / net income0.41x
Accruals ratio-35.9%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$16.80M$0
Cost of revenue$3.99M$0
Gross profit$12.81M$0
R&D expense$1.23M$1.18M
SG&A expense$42.45M$6.39M
Operating income-$32.43M-$7.57M
Interest expense$3.01M$786,000
Pretax income-$50.71M-$7.96M
Income tax-$7.39M$0
Net income-$43.32M-$7.96M
EBITDA-$31.70M-$7.57M
EPS (basic)-23.04-14.27
EPS (diluted)-23.04-14.27
Weighted avg. shares (diluted)1.88M557,447
Balance sheet
Cash & equivalents$17.97M$513,000
Receivables$8.86M$0
Inventory$23.57M$0
Current assets$53.41M$1.37M
PP&E, net$9.59M$0
Goodwill$24.68M$0
Intangibles$39.47M$0
Total assets$130.40M$1.37M
Current liabilities$25.99M$4.08M
Total liabilities$91.52M$4.08M
Shareholders' equity$38.88M-$2.71M
Shares outstanding3.23M610,389
Cash flow statement
Operating cash flow-$22.59M-$5.79M
Capital expenditure$99,000$0
Free cash flow-$22.69M-$5.79M
Investing cash flow-$5.24M$0
Financing cash flow$45.34M$6.21M
Depreciation & amortization$729,000$0
Stock-based compensation$5.46M$1.80M
Share buybacks$0$75,000

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.